Tokyo

London

New York

finscreener facebook fan page

finscreener twitter page

finscreener linkedin page

Atara Biotherapeutics, Inc.

TRADE

NASDAQ: ATRAHealthcare / Biotechnology / USA
38.35+2.78+7.82%Vol 319 6221Y Perf 163.57%
Oct 16th, 2018 16:00
BID37.01 ASK39.81
Open36.06 Previous Close35.57
Pre-Market- After-Trading38.35
 - -%  - -%
Target Price
49.00 
Analyst Rating
Moderate Buy 2.14
Potencial %
27.77 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12M
-94/-97/-99 
Value Ranking
 —    -
Insiders Value % 3/6/12M
-97/-99/-99 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12M
-96/-99/-99 
Income Ranking
 —    -
Market Cap (mil)1 739 
Earnings Rating
Strong Sell
Price Range Ratio 52wk %
61.48 
Earnings Date
8th Nov 2018

Today's Price Range

35.5038.48

 

52wk Range

12.6554.45

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Month
-1.92%
3 Months
-5.31%
6 Months
-6.92%
1 Year
163.57%
3 Years
30.18%
5 Years
-

Quotes

Name / TickerPriceChg.Chg.%
ATRA38.352.78007.82
AAPL222.154.79002.20
GOOG1 121.2829.03002.66
MSFT111.003.40003.16
XOM81.200.38000.47
WFC53.730.49000.92
JNJ136.562.61001.95
FB158.785.26003.43
GE12.10-0.0500-0.41
JPM108.622.28002.14
Financial StrengthValueIndustryS&P 500US Markets
Quick Ratio 15.30
Current Ratio 15.60
Long Term Debt to Total Capital -
Total Debt to Equity -
Interest Coverage -
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
Gross Margin-
EBIT Margin-
EBITDA Margin-
Pre-tax Profit Margin-
Profit Margin-
ValuationValueIndustryS&P 500US Markets
PE Ratio -
PB Ratio 3.65
PS Ratios -
Price to Cash Flow -
Price to Free Cash Flow -12.10
Cash Flow Per Share -3.29
Price to Tangible Book3.65
Book Value per Share9.98
Enterprise Value (in ths.)1 234 360
Management EffectivenessValueIndustryS&P 500US Markets
Return on Equity (5Y Avg)-37.71
ROE last 12 Months -46.78
Return on Assets (5Y Avg) -16.17
ROA last 12 Months -42.76
Return on Capital (5Y Avg) -
ROC last 12 Months -47.13
Return on invested Capital Q -11.41
Return on invested Capital Y-55.37
Assets Turnover0.00
Receivables Turnover-
RevenueValueIndustryS&P 500US Markets
Revenue LTM (in ths.)0
Revenue per Share 0.00
Revenue Growth 3 Years -
Revenue Growth 5 Years -
DividendsValueIndustryS&P 500US Markets
Dividend Yield -
Dividend Rate -
Dividend Growth 3 Years-
Dividend Growth 5 Years-

Earnings HistoryEstimateReportedSurprise %
Q02 2018-0.97-1.15-18.56
Q01 2018-0.93-1.05-12.90
Q04 2017-1.15-1.150.00
Q03 2017-1.03-1.020.97
Q02 2017-0.91-0.94-3.30
Q01 2017-0.77-0.88-14.29
Q04 2016-0.91-0.6330.77
Q03 2016-0.79-0.88-11.39
Earnings Per EndEstimateRevision %Trend
9/2018 QR-1.18-18.00Negative
12/2018 QR-1.21-16.35Negative
12/2018 FY-4.58-12.81Negative
12/2019 FY-5.12-17.97Negative
Next Report Date8th Nov 2018
Estimated EPS Next Report-1.18
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume319 622
Shares Outstanding (in ths.)45 340
Trades Count1 335
Dollar Volume6 800 766
Avg. Volume719 424
Avg. Weekly Volume404 764
Avg. Monthly Volume678 741
Avg. Quarterly Volume558 033

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

67%33%

Bearish Bullish

62%38%

Bearish Bullish

54%46%

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (57.14 %)
4 (57.14 %)
4 (57.14 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
2 (28.57 %)
2 (28.57 %)
2 (28.57 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (14.29 %)
1 (14.29 %)
1 (14.29 %)
RatingModerate Buy
2.14
Moderate Buy
2.14
Moderate Buy
2.14

There are no comments yet.

News

x